# OnCo record paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025" ;
  schema:name "Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial"@en ;
  schema:alternateName "ENRICH"@en, "Lewis 2025"@en ;
  schema:description "The first trial to show that a chemotherapy-free first-line combination beats immunochemotherapy in older people with mantle cell lymphoma."@en ;
  schema:url <https://onco.cc/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(25)01432-1>, <https://pubmed.ncbi.nlm.nih.gov/41052510/>, <https://europepmc.org/article/MED/41052510> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(25)01432-1> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Lewis DJ, Jerkeman M, Sorrell L, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/ccnd1/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/> ;
  onco:institutions <https://onco.cc/institutions/cruk/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/> ;
  onco:terms <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/maintenance-therapy/> ;
  onco:trials <https://onco.cc/trials/enrich/>, <https://onco.cc/trials/shine/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-aging-comorbidity/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-trial-diversity/> ;
  onco:journals <https://onco.cc/journals/lancet/> .